We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Astellas Pharma has successfully completed the previously announced acquisition of Audentes Therapeutics, through a tender offer by its indirect wholly-owned subsidiary Asilomar Acquisition for all of the issued and outstanding shares of common stock of .